ledoxantrone

03/15/2001 - "Phase I study of CI-958 in children and adolescents with recurrent solid tumors."
06/01/2001 - "Patients received CI-958 560 mg/m2 intravenously every 3 weeks and tumor measurements were performed every one to two cycles. "
03/15/2001 - "Children and adolescents with recurrent solid tumors received CI-958 at an initial dose of 450 mg/m(2) over 2 hours. "
12/01/2000 - "Patients received CI-958 560 mg/m(2) intravenously every 3 weeks and tumor measurements were performed every one to two cycles. "
12/01/2000 - "The objectives of this study were twofold: (1) to estimate the anti-tumor efficacy of CI-958 in patients with measurable platinum-resistant ovarian cancer; (2) to determine the nature and degree of toxicity of CI-958 in these patients. "

06/01/2001 - "To estimate the antitumor efficacy of CI-958 in patients with measurable recurrences of platinum-sensitive ovarian carcinoma and to determine the nature and degree of toxicity of CI-958 in these patients. "
04/01/2004 - "Phase II study of CI-958 in patients with hormone refractory prostate carcinoma."
06/01/2001 - "A phase II trial of CI-958 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study."
12/01/2000 - "Phase II trial of CI-958 in recurrent platinum-refractory ovarian carcinoma. "
06/01/2001 - "CI-958 has minimal activity in recurrent platinum-sensitive ovarian carcinoma at the dose and schedule tested."

12/01/2000 - "CI-958 has minimal activity in platinum-resistant ovarian cancer at the dose and schedule tested."
12/01/2000 - "The objectives of this study were twofold: (1) to estimate the anti-tumor efficacy of CI-958 in patients with measurable platinum-resistant ovarian cancer; (2) to determine the nature and degree of toxicity of CI-958 in these patients. "

01/01/1999 - "Phase II study of CI-958 in colorectal cancer."
12/01/2000 - "Our results show that at this dose and schedule, CI-958 lacks activity against colorectal cancer."
01/01/1999 - "CI-958 was not effective at this dose and schedule in patients with previously treated advanced colorectal cancer."
01/01/1999 - "We completed a phase II trial of CI-958 (NSC 635371) in patients with advanced colorectal cancer given at a dose of 700 mg/m2 every 21 days. "
12/01/2000 - "In a multicenter, phase II trial, CI-958, a benzothiopyranoindazole DNA intercalator, was administered to 18 patients who had not received prior chemotherapy for metastatic colorectal cancer. "

01/01/1998 - "Antihelicase action of CI-958, a new drug for prostate cancer."
01/01/1999 - "A phase II trial of CI-958 in patients with hormone-refractory prostate cancer."
01/01/1998 - "CI-958, a new DNA-intercalating drug derived from a series of substituted 2H-[1] benzothiopyrano[4,3,2-cd]indazoles, is being tested in clinical trails because of its curative properties against murine solid tumor models and because it has demonstrated activity in a pilot phase II study of patients with hormone-refractory prostate cancer. "